{"entity":{"id":"nct05085028","kind":"trial","name":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung","aka":["REFINE-Lung"],"tldr":"A phase 3 trial in lung cancer, run by Imperial College London, now recruiting.","summary":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT05085028 by Imperial College London, with a registry enrolment figure of 1750 participants, started 2022-06-23 and due to reach its primary completion in 2027-05-31. Interventions recorded: Pembrolizumab 25 MG/ML [Keytruda]. Conditions listed: Lung Cancer, Nonsmall Cell. Primary outcome: Overall survival at 2 years. Lung eligibility wording from the registry: \"* Any patient ≥18yrs who has received 6 months of pembrolizumab treatment with or without chemotherapy for advanced Non small cell lung cancer who is planned to continue immunotherapy treatment because of continued benefit\". Sites: United Kingdom. United Kingdom sites listed: 37. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05085028","url":"https://clinicaltrials.gov/study/NCT05085028"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Royal Bournemouth Hospital (Bournemouth); Royal Sussex County Hospital (Brighton); Bristol Haematology and Oncology Centre (Bristol); Queen's Hospital (Burton-on-Trent); Cambridge University Hospitals NHS Foundation Trust (Cambridge); East Kent Hospitals University NHS Foundation Trust (Canterbury); Velindre Cancer Centre (Cardiff); Colchester Hospital (Colchester); Royal Derby Hospital (Derby); NHS Lothian (Edinburgh); Royal Devon and Exeter Hospital (Exeter); Beatson West of Scotland Cancer Centre (Glasgow) and 25 more."],"nct":"NCT05085028","phase":"3","setting":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design","sponsor":"Imperial College London","enrolled":1750,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05085028/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}